During clinical trials and after drug launch, cardiomyocyte toxicity remains the main cause of drug depletion. Although it is believed that a large proportion of cardiovascular diseases are caused by the environment; However, the causative environmental factors still have little to no distinctive characteristics. Therefore, how to detect potential myocardial toxicity is a crucial aspect of improving in vitro drug screening methods. As a substitute for primary cardiomyocytes and myocardial tissue, the human induced pluripotent stem cell (iPSC) in vitro model system has become a physiologically relevant and highly reproducible choice for cardiac toxicity testing. The differentiation of human induced pluripotent stem cells into cardiomyocytes is a very attractive in vitro model system. They form a synchronized cell monolayer that can reliably replicate drug-related cardiac physiological phenotypes by monitoring changes in intracellular calcium ion flow through a rapid fluorescence kinetics method. The evaluation of the curve changes in response to changes in calcium ion flow is crucial for detecting myocardial functional effects, and high content imaging is an important supplementary analytical method for monitoring changes in myocardial cell morphology and compound cytotoxicity.